Nanexa AB (NANEXA) AI Stock Analysis

• Market Cap: kr484.76M
• Dividend Yield: N/A
• Average Volume (3M): 266.98K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.39
• Revenue Growth: -60.33%
• EPS Growth: 58.04%
• Country: SE
• Employees: 13
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.08
• Shares Outstanding: 158,676,150
• 10 Day Avg. Volume: 346,691
• 30 Day Avg. Volume: 266,979
• PEG Ratio: 0.14
• Price to Book (P/B): 4.13
• Price to Sales (P/S): 12.03
• P/FCF Ratio: -5.37
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: kr3.00 ▼(-1.96% Downside)

Nanexa AB's overall stock score is primarily impacted by its weak financial performance, characterized by persistent losses and cash flow issues. While technical analysis indicates a positive short-term trend, the overbought RSI suggests caution. The company's valuation metrics further highlight financial struggles, with a negative P/E ratio and no dividend yield.

Positive Factors

Proprietary Technology

Nanexa's NEX-20 platform offers a competitive advantage by enhancing drug efficacy and safety, potentially attracting partnerships and collaborations.

Low Leverage

Low leverage provides financial stability and flexibility, allowing Nanexa to navigate financial challenges without excessive debt burden.

Partnership Revenue Model

Partnerships and licensing agreements provide a sustainable revenue stream, supporting long-term growth and innovation in drug delivery technologies.

Negative Factors

Persistent Losses

Ongoing losses and cash flow issues hinder profitability and limit the company's ability to invest in growth and development.

Negative Cash Flow

Negative operating and free cash flows indicate cash burn, which can strain resources and impact long-term financial health.

Revenue Contraction

Declining revenue and profit margins reflect operational challenges and may affect the company's ability to sustain growth and profitability.

Nanexa AB Business Overview & Revenue Model

Company Description

Nanexa AB (NANEXA) is a biotechnology company specializing in drug delivery systems, particularly in the development of its proprietary platform, NEX-20, designed to enhance the efficacy and safety of therapeutic compounds. The company operates primarily in the pharmaceutical sector, focusing on the formulation and delivery of biopharmaceuticals to improve patient outcomes. Nanexa's core products include advanced drug formulations that utilize its unique technology to optimize the release profiles of active pharmaceutical ingredients.

How the Company Makes Money

Nanexa AB generates revenue primarily through the development and commercialization of its drug delivery technologies. The company earns money by entering into partnerships and collaborations with pharmaceutical companies that seek to utilize its proprietary NEX-20 platform for their drug development programs. These partnerships often involve licensing agreements, research and development funding, and milestone payments upon achieving specific development goals. Additionally, Nanexa may receive royalties from the sales of products developed using its technology. The company's financial performance is also supported by government grants and investments aimed at fostering innovation in biotechnology.

Nanexa AB Financial Statement Overview

Summary

Nanexa AB faces significant financial challenges, with declining revenues, persistent losses, and cash flow difficulties. While the balance sheet shows manageable leverage, the negative profitability metrics and cash flow issues indicate a need for strategic improvements to achieve financial stability and growth.

Income Statement

Nanexa AB's income statement reveals significant challenges, with declining revenue growth and negative profit margins. The TTM data shows a revenue decline of 15.15%, and the company has consistently reported negative net profit margins, indicating ongoing profitability issues. Despite a relatively high gross profit margin, the negative EBIT and EBITDA margins highlight operational inefficiencies.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio, suggesting manageable leverage. However, the return on equity is negative, reflecting poor profitability relative to shareholder equity. The equity ratio is stable, indicating a solid asset base, but the company's financial health is undermined by persistent losses.

Cash Flow

Cash flow analysis indicates a challenging environment with negative operating cash flow and free cash flow. Although there is a slight improvement in free cash flow growth, the operating cash flow to net income ratio remains negative, highlighting cash generation issues. The free cash flow to net income ratio suggests some ability to cover net losses, but overall cash flow remains weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	10.58M	24.36M	29.33M	2.86M	2.37M	2.37M
Gross Profit	31.92M	46.69M	59.16M	3.40M	4.31M	20.86M
EBITDA	-24.15M	-18.99M	-70.79M	-53.86M	-32.92M	-16.28M
Net Income	-39.05M	-24.91M	-76.40M	-58.57M	-36.00M	-21.74M
Balance Sheet
Total Assets	114.06M	91.82M	132.26M	170.19M	165.00M	53.69M
Cash, Cash Equivalents and Short-Term Investments	24.78M	10.29M	65.17M	81.18M	105.66M	12.69M
Total Debt	21.37M	3.71M	4.03M	6.27M	3.83M	3.89M
Total Liabilities	36.72M	20.90M	36.43M	61.10M	13.70M	10.34M
Stockholders Equity	77.34M	70.92M	95.83M	109.10M	151.29M	43.35M
Cash Flow
Free Cash Flow	-58.29M	-54.55M	-76.91M	-43.29M	-50.92M	-37.63M
Operating Cash Flow	-31.39M	-26.43M	-42.66M	-7.87M	-25.13M	-16.83M
Investing Cash Flow	-26.90M	-28.12M	-34.25M	-35.42M	-25.79M	-20.80M
Financing Cash Flow	54.06M	-327.00K	60.89M	18.81M	143.89M	38.94M

Nanexa AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.06
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:NANEXA, the sentiment is Positive. The current price of 3.06 is above the 20-day moving average (MA) of 2.00, above the 50-day MA of 1.93, and above the 200-day MA of 1.93, indicating a bullish trend. The MACD of 0.28 indicates Negative momentum. The RSI at 74.30 is Negative, neither overbought nor oversold. The STOCH value of 90.28 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:NANEXA.

Nanexa AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NANEXA	50 Neutral	kr484.76M	-12.98	-48.65%	―	-60.33%	58.04%
ALZCUR	47 Neutral	kr252.81M	―	-90.66%	―	―	15.74%
KLAR	41 Neutral	€142.67M	-2.23	-530.21%	―	―	17.42%
ENZY	38 Underperform	kr446.63M	-8.07	―	―	19.17%	24.53%